These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28687901)

  • 1. Virological and Clinical Characteristics of Hepatitis B Virus Genotype A.
    Ito K; Yoneda M; Sakamoto K; Mizokami M
    J Gastroenterol; 2018 Jan; 53(1):18-26. PubMed ID: 28687901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
    Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
    J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults.
    Ito K; Yotsuyanagi H; Yatsuhashi H; Karino Y; Takikawa Y; Saito T; Arase Y; Imazeki F; Kurosaki M; Umemura T; Ichida T; Toyoda H; Yoneda M; Mita E; Yamamoto K; Michitaka K; Maeshiro T; Tanuma J; Tanaka Y; Sugiyama M; Murata K; Masaki N; Mizokami M;
    Hepatology; 2014 Jan; 59(1):89-97. PubMed ID: 23897861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
    J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological Characteristics of Acute Hepatitis B in Eastern India: Critical Differences with Chronic Infection.
    Sarkar N; Pal A; Das D; Saha D; Biswas A; Bandopadhayay B; Chakraborti M; Ghosh M; Chakravarty R
    PLoS One; 2015; 10(11):e0141741. PubMed ID: 26571502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic hepatitis B in pregnant women: is hepatitis B surface antigen quantification useful for viral load prediction?
    Fujiko M; Chalid MT; Turyadi ; Ie SI; Maghfira ; Syafri ; Wahyuni R; Roni M; Patellongi I; Massi MN; Muljono DH
    Int J Infect Dis; 2015 Dec; 41():83-9. PubMed ID: 26571304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection.
    Rodriguez-Frias F; Jardi R; Buti M; Schaper M; Hermosilla E; Valdes A; Allende H; Martell M; Esteban R; Guardia J
    J Viral Hepat; 2006 May; 13(5):343-50. PubMed ID: 16637866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
    Boglione L; Cardellino CS; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2014 Nov; 86(11):1845-50. PubMed ID: 25131947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C.
    Kao JH; Chen PJ; Lai MY; Chen DS
    J Clin Microbiol; 2002 Jan; 40(1):22-5. PubMed ID: 11773087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.
    Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Delaugerre C; Danel C; Zoulim F; Lacombe K;
    J Viral Hepat; 2018 Oct; 25(10):1121-1131. PubMed ID: 29660214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of hepatitis B virus genotype D in precore mutants among chronic liver disease patients from New Delhi, India.
    Kar P; Polipalli SK; Chattopadhyay S; Hussain Z; Malik A; Husain SA; Medhi S; Begum N
    Dig Dis Sci; 2007 Feb; 52(2):565-9. PubMed ID: 17211692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a.
    Moucari R; Martinot-Peignoux M; Mackiewicz V; Boyer N; Ripault MP; Castelnau C; Leclere L; Dauvergne A; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
    Antivir Ther; 2009; 14(8):1183-8. PubMed ID: 20032548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
    Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
    Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
    Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection.
    Song BC; Cui XJ; Kim H
    Intervirology; 2005; 48(2-3):133-7. PubMed ID: 15812186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of hepatitis B virus (HBV) genotypes for the disease and treatment outcome among patients with chronic hepatitis B in Serbia.
    Milosevic I; Delic D; Lazarevic I; Pavlovic IP; Korac M; Bojovic K; Jevtovic D
    J Clin Virol; 2013 Sep; 58(1):54-8. PubMed ID: 23838671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy.
    Hung CH; Chen CH; Lu SN; Wang JH; Hu TH; Huang CM; Tsai MC; Lee CM
    Antiviral Res; 2012 Jan; 93(1):55-63. PubMed ID: 22061616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.